Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorSloan, Derek J.
dc.contributor.authorParris, Victoria
dc.date.accessioned2018-03-27T14:30:04Z
dc.date.available2018-03-27T14:30:04Z
dc.date.issued2014-05-13
dc.identifier.citationSloan , D J & Parris , V 2014 , ' Cryptococcal meningitis : epidemiology and therapeutic options ' , Journal of Clinical Epidemiology , vol. 6 , pp. 169-182 . https://doi.org/10.2147/CLEP.S38850en
dc.identifier.issn0895-4356
dc.identifier.otherPURE: 241921155
dc.identifier.otherPURE UUID: 9f3b2fe0-9c0a-4af1-a573-283746c2f3b1
dc.identifier.otherScopus: 84900559961
dc.identifier.urihttps://hdl.handle.net/10023/13031
dc.description.abstractCryptococcal meningitis causes morbidity and mortality worldwide. The burden of disease is greatest in middle- and low-income countries with a high incidence of human immunodeficiency virus (HIV infection. Patients taking immunosuppressive drugs and some immunocompetent hosts are also at risk. Treatment of cryptococcal meningitis consists of three phases: Induction, consolidation, and maintenance. Effective induction therapy requires potent fungicidal drugs (amphotericin B and flucytosine, which are often unavailable in low-resource, high-endemicity settings. As a consequence, mortality is unacceptably high. Wider access to effective treatment is urgently required to improve outcomes. For human immunodeficiency virus-infected patients, judicious management of asymptomatic cryptococcal antigenemia and appropriately timed introduction of antiretroviral therapy are important.
dc.format.extent14
dc.language.isoeng
dc.relation.ispartofJournal of Clinical Epidemiologyen
dc.rights© 2014 Sloan and Parris. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.phpen
dc.subjectAntifungal therapyen
dc.subjectAntiretroviral therapyen
dc.subjectCryptococcosisen
dc.subjectHIVen
dc.subjectImmune reconstitution inflammatory syndromeen
dc.subjectImmunosuppressionen
dc.subjectRA0421 Public health. Hygiene. Preventive Medicineen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectEpidemiologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccRA0421en
dc.subject.lccRMen
dc.titleCryptococcal meningitis : epidemiology and therapeutic optionsen
dc.typeJournal itemen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.identifier.doihttps://doi.org/10.2147/CLEP.S38850
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record